Makiz-Pharma

Makiz-Pharma is a prominent Russian pharmaceutical manufacturer specializing in the development and large-scale production of high-quality generic medications. Established in 2001 and headquartered in Moscow, the company operates a modern manufacturing facility certified under international Good Manufacturing Practice (GMP) standards. In 2007, Makiz-Pharma was acquired by the Pharmstandard group, one of Russia's largest pharmaceutical companies, for approximately $135 million. The company's extensive product portfolio covers critical therapeutic areas including cardiology, neurology, urology, and gastroenterology. Notably, Makiz-Pharma is a key producer of antiretroviral therapies for HIV treatment in the Russian market. In addition to its own branded generics, the company provides contract manufacturing services for both domestic and international pharmaceutical partners.